ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center
Research & Reviews 231 results
Blood Advani RH, Skrypets T et. al.
Jul 23rd, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018...
https://doi.org/10.1038/s41375-021-01321-2 10.1182/blood-2016-09-692541 10.1182/blood-2016-01-643569 10.1200/JCO.2011.37.3647 10.1038/s41375-020-0990-y 10.1097/MD.0b013e3181573059 10.1016/j.semcancer.2013.11.004 10.1038/ng.2873 10.1038/ng.2872 10.1038/ng.2916 10.1073/pnas.1617929114 10.1182/blood-2017-11-818617 10.1002/path.4898 10.1002/path.4920 10.1002/path.5376 10.1182/blood-2018-04-843714 10.1038/s41467-020-14919-4 10.1038/s41598-020-57741-0 10.1371/journal.pone.0177405 10.1002/eji.201242648 10.1016/j.celrep.2019.01.085 10.1038/nbt.2594 10.3389/fimmu.2019.01315 10.1016/j.cell.2018.11.043 10.1038/s41591-018-0057-z 10.1038/s41586-019-1836-5 10.1073/pnas.1913940117 10.1016/j.cyto.2014.11.010 10.3389/fimmu.2019.01088 10.1016/j.micinf.2011.10.003 10.3389/fimmu.2012.00014 10.1038/srep23505 10.1038/s41416-020-0757-2 10.1097/01.pai.0000173053.45296.51 10.1016/j.it.2013.11.001 10.1189/jlb.5A0816-346R 10.1371/journal.pone.0092009 10.1172/JCI79380 10.3960/jslrt.55.61
Leukemia Pritchett JC, Yang ZZ et. al.
Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive lymphoid malignancy associated with a poor clinical prognosis. The AITL tumor microenvironment (TME) is unique, featuring a minority population of malignant CD4+ T follicular helper (TFH) ...
Current Opinion in Oncology; Tari G, Lemonnier F et. al.
Jul 8th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent peripheral T-cell lymphoma affecting elderly patients with a poor outcome when treated with conventional chemotherapy. Molecular studies revealed a homogenous mutational landscape gathering a...
American Journal of Clinical Pathology; Xie Y, Jaffe ES
Jun 13th, 2021 - Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma derived from T-follicular helper cells. For pathologists, diagnosing AITL may be challenging due to its wide clinical and histopathologic spectrum, which can mimi...
The Journal of International Medical Research; Sun J, He S et. al.
May 27th, 2021 - To explore prognostic factors and develop an accurate prognostic prediction model for angioimmunoblastic T-cell lymphoma (AITL). Clinical data from Chinese patients with newly diagnosed AITL were retrospectively analysed. Overall survival (OS) and...
Clinicaltrials.gov 10 results
May 4th, 2020 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of MEDI-570 (anti-ICOS monoclonal antibody MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...
Mar 4th, 2020 - This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. The first 18 subjects may be of the following PTCL sub-types: PTCL not otherwise specified (PTCL-NOS), angioimm...
Sep 10th, 2019 - PRIMARY OBJECTIVES: I. To assess the safety and efficacy of lenalidomide in combination with standard induction therapy (CHOEP- cyclophosphamide, doxorubicin [doxorubicin hydrochloride], etoposide, vincristine [vincristine sulfate] and prednisone)...
Sep 10th, 2018 - This is a multi-center, prospective, non-randomized, open-label, Phase 2 clinical study to evaluate the safety and efficacy of BGB-A317 in patients with relapsed or refractory mature T- and natural killer (NK)-cell neoplasms. There will be two coh...
Sep 6th, 2018 - Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of nodal and extranodal mature T-cell lymphomas, which constitute about 5 - 10% of all non-Hodgkin lymphomas (NHLs) in Western countries compared to 20 - 30% of all lymphomas in th...
News 20 results
Sep 11th, 2019 - Registries for T-cell lymphoma have improved our understanding of the disease, but many questions remain. Could combining the various registries provide more answers? “[T]here are many, many different registries around the world,” said Owen O’Conn.
Ermann DA, Vardell VA et. al.
Sep 9th, 2019 - Background: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive malignancy, representing approximately 18. 5% of Peripheral T-cell lymphomas.
Aug 9th, 2019 - LUGANO, SWITZERLAND – A combination of 5-azacytidine and romidepsin showed promising activity in patients with peripheral T cell lymphomas, particularly angioimmunoblastic T-cell lymphoma (AITL) and primary cutaneous follicular helper T-cell lymph.
Feb 6th, 2019 - LA JOLLA, CALIF. – The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas.
Feb 5th, 2019 - Efficacy with romidepsin Among all evaluable PTCL patients in the romidepsin arm, the ORR was 59% (16/27), and the CR rate was 33% (9/27). Responses occurred in seven patients with PTCL not otherwise specified (NOS), six with angioimmunoblastic T-.